Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
Status:
COMPLETED
Trial end date:
2025-08-19
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, single-center, repeated i.v. doses, Phase 1 trial to evaluate the pharmacokinetics, safety, and tolerability of a combination of MEM-ANT3310 in healthy adult female and male participants who will undergo a single bronchoalveolar lavage (BAL) via a standardized fiberoptic bronchoscopy to evaluate and compare the pharmacokinetics characteristics of ANT3310 and meropenem (MEM) in plasma and epithelial lining luid (ELF).